Drug companies take years, even decades and burn a tremendous amount of cash to bring a drug to the market. Some drugs pass the FDA muster easily, while some struggle through the stringent review process. However, despite the regulatory setbacks, some companies exude a steely determination to bring their drugs to market.
The company we are profiling today is Aldeyra Therapeutics Inc. (ALDX), which, being twice denied FDA approval for its first-in-class investigational eye drop, Reproxalap, isn't backing down.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.